Richard Lindstrom

Summary

Affiliation: Minnesota Eye Consultants
Country: USA

Publications

  1. doi request reprint Corneal inlays for presbyopia correction
    Richard L Lindstrom
    Minnesota Eye Consultants, Bloomington, MN 55431, USA
    Curr Opin Ophthalmol 24:281-7. 2013
  2. ncbi request reprint Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac
    Richard Lindstrom
    Minnesota Eye Consultants, Minneapolis, MN 55904, USA
    Curr Med Res Opin 22:397-404. 2006
  3. ncbi request reprint The pharmacologic and pathophysiologic rationale for using NSAIDs in ocular inflammatory disease and ocular surgery
    Richard Lindstrom
    Minnesota Eye Consultants, Minneapolis, MN 55404, USA
    Int Ophthalmol Clin 46:7-11. 2006
  4. doi request reprint Conjunctival concentrations of a new ophthalmic solution formulation of moxifloxacin 0.5% in cataract surgery patients
    Richard Lindstrom
    Minnesota Eye Consultants, Minneapolis, Minnesota, USA
    J Ocul Pharmacol Ther 26:591-5. 2010
  5. doi request reprint Double-masked comparison of ketorolac tromethamine 0.4% versus nepafenac sodium 0.1% for postoperative healing rates and pain control in eyes undergoing surface ablation
    Richard Lindstrom
    Cornea 27:385-6; author reply 386-7. 2008

Detail Information

Publications5

  1. doi request reprint Corneal inlays for presbyopia correction
    Richard L Lindstrom
    Minnesota Eye Consultants, Bloomington, MN 55431, USA
    Curr Opin Ophthalmol 24:281-7. 2013
    ..This study provides an overview of the three types of corneal inlays now in use for the correction of presbyopia and reviews recently published evidence of the inlays' safety and efficacy...
  2. ncbi request reprint Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac
    Richard Lindstrom
    Minnesota Eye Consultants, Minneapolis, MN 55904, USA
    Curr Med Res Opin 22:397-404. 2006
    ..Preclinical data suggest nepafenac may also provide unique efficacy in the posterior segment...
  3. ncbi request reprint The pharmacologic and pathophysiologic rationale for using NSAIDs in ocular inflammatory disease and ocular surgery
    Richard Lindstrom
    Minnesota Eye Consultants, Minneapolis, MN 55404, USA
    Int Ophthalmol Clin 46:7-11. 2006
  4. doi request reprint Conjunctival concentrations of a new ophthalmic solution formulation of moxifloxacin 0.5% in cataract surgery patients
    Richard Lindstrom
    Minnesota Eye Consultants, Minneapolis, Minnesota, USA
    J Ocul Pharmacol Ther 26:591-5. 2010
    ..5% (Moxi) or a new 0.5% ophthalmic solution formulation (MAF) containing a retention-enhancing agent in patients undergoing cataract surgery...
  5. doi request reprint Double-masked comparison of ketorolac tromethamine 0.4% versus nepafenac sodium 0.1% for postoperative healing rates and pain control in eyes undergoing surface ablation
    Richard Lindstrom
    Cornea 27:385-6; author reply 386-7. 2008